期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吡格列酮对DSS诱导的炎症性肠病小鼠血清TNF-α与hs-CRP水平的影响 被引量：3

下载PDF
导出
摘要 目的观察吡格列酮对炎症性肠病小鼠血清肿瘤坏死因子-α(TNF-α)与高敏C反应蛋白(hs-CRP)水平的影响,探讨吡格列酮可能成为治疗炎症性肠病的药物及降低远期动脉粥样硬化的发病风险。方法清洁BALB/c小鼠随机分为3组,分别为正常组、模型组、吡格列酮药物干预组。采用3%DSS溶液制备炎症性肠病小鼠模型,在造模第2天开始给予吡格列酮25 mg/kg灌胃,每天一次,直至实验结束。治疗结束后,采用酶联免疫法(ELISA法)检测血清hs-CRP、TNF-α。结果与正常组相比较,模型组小鼠肠组织出现炎症性表现,且血清hs-CRP、TNF-α的水平均显著增高(P<0.01);与模型组相比较,吡格列酮干预组小鼠肠道炎症表现明显减轻,且血清hs-CRP、TNF-α的水平均显著降低(P<0.01)。结论吡格列酮能下调炎症性肠病小鼠TNF-α的表达,减轻肠道炎症性改变,并改善肠道组织形态结构,而发挥治疗,明显降低血清hs-CRP的水平,降低远期动脉粥样硬化的风险。
作者 刘亭亭 陈还珍 马文艳 忽海洋
机构地区 山西医科大学第一医院
出处 《中西医结合心脑血管病杂志》 2015年第1期61-62,77,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词 炎症性肠病 高敏C反应蛋白 肿瘤坏死因子-α 吡格列酮
分类号 R574 [医药卫生—消化系统] R285.5 [医药卫生—中药学]
  • 相关文献

参考文献14

  • 1欧阳钦,胡品津,钱家鸣,郑家驹,胡仁伟.对我国炎症性肠病诊断治疗规范的共识意见[J].胃肠病学,2007,12(8):488-495. 被引量：751
  • 2Zheng JJ,Zhu XS,Huang FZ,et al. Crohn’s disease in main-land China: A systematic analysis of 50 years of research [J].Chin J Dig Dis,2005,6(4) :175-181.
  • 3Young Y’Adreu MT. Advances in the pathogenesis of inflamma-tory bowel disease[J]. Curr Gastroenterol Rep, 2006, 8(6): 470 -477.
  • 4Van Assche G,Vermeire S, Rutgeerts P. Focus on mechanismsof inflammation in inflammatory bowel disease sites of inhibition:Current and future therapies[J]. Gastroenterol Clin North Am,2006,35(4):743 - 756.
  • 5Li Z,Zhang de K,Yi WQ,ef al. HF - kappaB p65 antisense oli-gonucleotides may serve as a novel molecular approach for thetreatment of patients with ulcerative colitis[J], Arch Med Res,2008,39(8):729-734.
  • 6Tanaka K. Expression of Toll - like receptors in the intestinalmucosa of patients with inflammatory bowel disease[J]. ExpertRev Gastroenterol Hepatol,2008,2(2) : 193 - 196.
  • 7Himmel ME,Hardenberg G,Piccirillo CA,et al. The role of T -regulatory cells and Toll - like receptors in the pathogenesis ofhuman inflammatory bowel disease[J]. Immunology,2008,125(2):145-153.
  • 8Fajas L,Auboeuf D,Raspe E,et al. The organization, promoteranalysis and expression of the human PPARgamma gene[J]. JBiol Chem ,1997,272( 30) : 18779 - 18789.
  • 9Shibolet O,Podolsky DK. TLRs in the Gut IV Negative regulationof Toll - like receptors and intestinal homeostasis: Addition bysubtraction[J]. Am J Physiol Gastrointest Liver Physiol,2007,292(6) :G1469-1473.
  • 10Wada K,Nakajima A,Blumberg RS. PPAR and inflammatorybowel disease: A new therapeutic target for ulcerative colitisand Crohn’s disease[J]. Trends Mot Med, 2001,7(8): 329-331.

二级参考文献18

  • 1潘国宗 刘彤华 见:潘国宗 曹世植9. 主编.溃疡性结肠炎[A].见:潘国宗,曹世植9.,主编.现代胃肠病学.第Ⅰ版[C].北京:科学出版社,1994.1246-1247.
  • 2潘国宗 刘彤华.Crohn病[A].见:潘国宗 曹世植 主编.现代胃肠病学[C].北京:科学出版社,1994.1154.
  • 3Ouyang Q,Tandon R,Goh KL,et al.The emergence of inflammatory bowel disease in the Asian Pacific region.Curr Opin Gastroenterol,2005,21 (4):408-413.
  • 4Satsangi J,Silverberg MS,Vermeire S,et al.The Montreal classification of inflammatory bowel disease:controversies,consensus,and implications.Gut,2006,55(6):749-753.
  • 5Kornbluth A,Sachar DB; Practice Parameters Committee of the American College of Gastroenterology.Ulcerative colitis practice guidelines in adults (update):American College of Gastroenterology,Practice Parameters Committee.Am J Gastroenterol,2004,99 (7):1371-1385.
  • 6Hanauer SB,Sandborn W; Practice Parameters Committee of the American College of Gastroenterology.Management of Crohn's disease in adults.Am J Gastroenterol,2001,96 (3):635-643.
  • 7Stange EF,Travis SP,Vermeire S,et al.European Crohn's and Colitis Organisation.European evidence based consensus on the diagnosis and management of Crohn's disease:definitions and diagnosis.Gut,2006,55Suppl 1:i1-i15.
  • 8Carter MJ,Lobo AJ,Travis SP; IBD Section,British Society of Gastroenterology.Guidelines for the management of inflammatory bowel disease in adults.Gut,2004,53 Suppl 5:V1-V16.
  • 9Shivananda S,Hordijk ML,Ten Kate FJ,et al.Differential diagnosis of inflammatory bowel disease.A comparison of various diagnostic classifications.Scand J Gastroenterol,1991,26 (2):167-173.
  • 10樋渡信夫 渡边浩光 前川浩树 等.溃疡性结肠炎的诊断标准与诊断进展[J].炎症性肠疾患胃与肠,1997,32(3):271-278.

共引文献750

同被引文献35

  • 1Neeraj Kumar Agrawal,Saket Kant.Targeting inflammation in diabetes: Newer therapeutic options[J].World Journal of Diabetes,2014,5(5):697-710. 被引量：42
  • 2孙彬,王蕴红.NF-κB与炎症性疾病和心脏病的关系[J].菏泽医学专科学校学报,2006,18(4):87-89. 被引量：1
  • 3Lorenzo O, Picatoste B, Ares-Carrasco S, ct al. Potential role of nuclear factor KB in diabetic cardi0myopathy [ J ]. Mediators Inflammation,2011,2011:652097.
  • 4Boudina S,Abel ED. Diabetic cardiomyopathy ,causes and effects [ J ]. Reviews in Endocrine and Metabolic Disor- ders,2010,11 (1) :31.
  • 5Zhong P, Wu L, Qian Y, et al. Blockage of ROS and NF- KB-mediated inflammation by a new chalcone L6H9 pro- tects cardiomyocytes from hyperglycemia-induced injuries [ J ]. Biochimica et Biophysica Acta (BBA)-MolecularBasis of Disease ,2015,28,1852(7 ) : 1230.
  • 6Giuliani C, Napolitano G, Bucci I, et al. NF-:B transcrip- tion factor:role in the pathogenesis of inflammatory, auto- immune ,and neoplastic diseases and therapy implications [ J]. La Clinica Terapeutiea,2000,152(4) :249.
  • 7Ulivi V, Giannoni P, Gentili C, et al. p38/NF-kB-depend- ent expression of COX-2 during differentiation and inflam- matory response of chondrocytes [ J ]. Journal of Cellular Biochemistrv. 2008.104 (4) : 1393.
  • 8谭毅,王越晖,李校堃,蔡露.心脏炎症反应在糖尿病心肌病发生发展中的病理作用[J].中国糖尿病杂志,2008,16(4):250-256. 被引量：9
  • 9周国胜,吴正祥.一氧化氮与炎症性肠病[J].安徽医药,2008,12(11):1010-1012. 被引量：7
  • 10张凤,冉志华.炎症性肠病的胃肠动力学改变[J].胃肠病学和肝病学杂志,2009,18(10):875-878. 被引量：5

引证文献3

二级引证文献31

中西医结合心脑血管病杂志
2015年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部